Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a Healthcare company (Biotechnology) with a market capitalization of $4.9B. The Maz Rating grades it against the other companies in its sector.
Dianthus Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $86.98, Dianthus Therapeutics, Inc. trades at 2898.5x trailing earnings, 1801.6x sales and 4.0x book value. Over the last twelve months it generated about $3M of revenue and $2M of net income. It runs a gross margin of 97.2%, an operating margin of -8683.9% and a net margin of -1463.8%. It shows return on equity of -3.9%, return on invested capital of -18.9% and a free cash flow yield of -3.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 30.02. Over the past 52 weeks the share price ranged from $35.84 to $117.88, with a beta of 0.08.
Dianthus Therapeutics, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 1 Strong Buy and 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Dianthus Therapeutics, Inc. (DNTH) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.8% / 30% · Interest income / Revenue 1003.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.0% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 1003.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.0% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 1003.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.05% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.9% / 33.33% · Receivables / Avg Assets (4Q) 0.05% / 33.33% · Interest income / Revenue 1003.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 65.6% / 33.33% · (Cash+Recv) / Total Assets 65.7% / 33.33% · Interest income / Revenue 1003.6% / 5% | Fail |
No. As of September 2026, Dianthus Therapeutics, Inc. (DNTH) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Dianthus Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 1003.6% of each dividend: Dianthus Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.